GIG HARBOR, Wash., March 27, 2026 (GLOBE NEWSWIRE) -- IP Strategy Holdings, Inc. (Nasdaq: IPST) (the “Company”) today highlighted recent progress from GenoBank.io, a Story ecosystem project bringing genomic data onchain. GenoBank is expanding its BioIP platform on Story, enabling genomic data to be registered as programmable digital assets that individuals can own, license, and monetize. The platform supports more than 7,000 genomic accounts, 150+ research partnerships, and over $6.9 million in tokenized Bi ...

BNGO stock is soaring. See the chart and price action here. Despite a slight year-over-year revenue dip, the stock showed resilience, gaining nearly 27% in Monday’s regular session.The Financials: Narrowing the GapFor the fourth quarter, Bionano reported revenue of $8 million, landing at the high end of its previous guidance. While this was a 3% decrease from the prior year, the real victory was in the margins. Full-year gross margins skyrocketed to 46%, a massive leap from the 1% seen in 2024.The improveme ...

Core Viewpoint - Bionano Genomics, Inc. is a life sciences company focused on genome analysis, providing essential tools and services for genetic research, which are vital for understanding genetic diseases and developing treatments [1] Financial Performance - Bionano is set to release its quarterly earnings on March 23, 2026, with Wall Street estimating a loss of $2.47 per share and analysts predicting a smaller loss of $1.40 per share [2][6] - Revenue projections are closely aligned, with Wall Street expecting $7.88 million and analysts estimating $7.85 million, while the company previously projected revenue between $7.8 million and $8.0 million [2] Stock Valuation - The current stock price of Bionano is $1.12, with a negative price-to-earnings (P/E) ratio of -0.16 and a price-to-sales ratio of 0.13, indicating the stock is valued at 13 cents for every dollar of sales [3][6] - The enterprise value to sales ratio is 0.28, reflecting the company's valuation relative to its revenue [3] Financial Health Indicators - The enterprise value to operating cash flow ratio is around -0.43, indicating negative cash flow [4] - The debt-to-equity ratio is 0.15, suggesting low debt levels, while the current ratio of 2.12 indicates good short-term financial health, with more than twice the current assets compared to liabilities [4][6] Analyst Ratings - Analyst Yi Chen from HC Wainwright and Co. maintains a Buy rating on Bionano, although the price target was reduced from $11 to $7 in November 2025 [5] - Bionano will host a conference call and webcast on March 23, 2026, to discuss its financial results and corporate progress, with CEO Erik Holmlin participating [5]

Core Viewpoint - Bionano Genomics, Inc. is expected to report a quarterly loss and specific revenue figures for the fourth quarter and fiscal year 2025 [1] Financial Performance - The company is anticipated to report a quarterly loss of $1.40 per share [1] - Expected revenue for the fourth quarter is between $7.8 million and $8.0 million, with a consensus estimate of $7.85 million [1] - For fiscal year 2025, total revenue is projected to be between $28.4 million and $28.6 million [1] Stock Information - Bionano Genomics shares closed at $1.12 on the last trading day [1]

Core Insights - The article discusses the 15 most promising stocks under $100 to buy, highlighting their potential for growth and recent developments that may impact investor sentiment. Group 1: GeneDx Holdings Corp. (NASDAQ:WGS) - GeneDx Holdings Corp. has partnered with Zevra Therapeutics to launch a genetic testing program for Niemann-Pick disease type C, aiming to expand access to its ExomeDx test for patients in the US [7][8]. - The program seeks to provide high-quality exome sequencing at no charge to eligible patients, facilitating quicker diagnoses and informed clinical decision-making [7][8]. - De-identified data from the testing will be integrated into GeneDx Infinity, enhancing understanding of disease biology and accelerating the journey from diagnosis to treatment [9]. Group 2: Booz Allen Hamilton Holding Corporation (NYSE:BAH) - Booz Allen Hamilton announced an investment in Hadean, a UK-based tech firm specializing in AI-powered digital wargaming, marking its first international investment [11]. - This collaboration aims to modernize military training and mission rehearsals for the US and its allies through advanced synthetic environments [12]. - The technologies developed are intended to replace legacy systems with scalable and secure capabilities, with applications across defense, civil, intelligence, and national security sectors [13].

Core Insights - ProPhase Labs is experiencing significant engagement with over 250 insurance payors regarding its Crown Medical Collections initiative, with approximately 100 cases in active settlement discussions [2][4][6] - The company is exploring institutional financing options secured by its receivables platform, which may enhance financial flexibility [4][6] - Management is focused on stabilizing liquidity, managing liabilities, and advancing key assets, including its esophageal cancer diagnostic [5][6] Group 1 - The company reports positive progress in its Crown Medical Collections efforts, with ongoing discussions reflecting a compelling asset for potential financing [2][4] - Current activities align with the company's recovery framework and internal estimates, indicating tangible progress [3][6] - The level of diligence from potential financing sources suggests growing external validation of the receivables as an asset [4] Group 2 - ProPhase Labs is committed to executional excellence and innovation in healthcare, focusing on whole genome sequencing and diagnostic development [7] - The company aims to build a healthier world through its health and wellness solutions, emphasizing a synergistic approach [7] - Future updates are expected as developments in the Crown Medical Collections initiative continue [6]

Core Insights - The Alliance for Genomic Discovery (AGD) has expanded its dataset to over 312,000 whole genomes with longitudinal clinical data, with Regeneron Genetics Center (RGC) joining as the tenth member [1] - A new initiative will add 50,000 whole genomes paired with proteomic data, with GSK being one of the first participants in this multiomic expansion [1] - The integration of high-quality clinical and genomic data with advanced AI is expected to enhance drug discovery and patient outcomes [1] Dataset Expansion - The AGD dataset is now one of the largest collections of whole genome sequences, enriched with clinical data from a leading academic medical center [1] - The addition of RGC will significantly scale the database, which already includes nearly 3 million sequenced exomes and de-identified electronic health records (EHRs) [1] - The dataset aims to facilitate precise disease cohort definitions and has already contributed to discoveries in autoimmune diseases and obesity [1] Proteomics Initiative - The new dataset will consist of 50,000 paired whole-genome and proteomic samples, enhancing the molecular depth of the AGD dataset [1] - This initiative is designed to accelerate target discovery and therapy development by providing deeper biological insights [1] - The diverse genetic ancestry within AGD allows for the study of population-specific genetic variants and their associated proteins [1] Collaboration and Goals - RGC aims to uncover large-effect protective genetic factors to identify high-confidence drug targets [1] - The collaboration reflects ongoing partnerships with Illumina and the biopharma community to build large-scale population genomics consortia [1] - The integration of proteomics with comprehensive datasets is expected to pinpoint drug targets linked to human diseases [1]

Core Perspective - Tempus is positioned as a unique player in the healthcare sector, integrating genomics with a large multimodal longitudinal clinically annotated data set, enhanced by AI technology [1] Company Overview - Tempus is recognized primarily as a genomics company, which still constitutes a significant portion of its revenue [1] - The company has evolved to incorporate AI into its operations, suggesting a broader focus beyond just diagnostics [1] Industry Context - The integration of AI into healthcare data management is becoming increasingly important, with companies like Tempus leading the way in this transformation [1] - The discussion highlights the potential for AI to enhance the utility of existing healthcare data, particularly in oncology [1]

Core Insights - The company achieved a 22% total revenue growth in Q4 2025, primarily driven by a 31% increase in clinical revenue as the core business re-accelerated toward historical levels [1] - The company processed nearly 1 petabyte of genomic data in 2025, doubling the volume from two years ago due to a market shift toward large comprehensive panels and multi-omic analysis [1] - The adjusted gross margin expanded by 140 basis points to 74.2% through a major architectural modernization that increased compute capacity tenfold and reduced whole genome analysis time to under 6 hours [1] Business Development - The company secured two of the largest integrated health systems in the US, representing a combined potential of 60,000 annual genomic tests and 1 million oncology/rare disease patients [1] - The company maintained high platform stickiness with an annualized revenue churn below 1% and a Net Promoter Score of 67, validating the decentralized AI deployment model [1] Leadership Transition - A leadership transition was announced with Ross Muken set to become CEO in July 2026, while founder Jurgi Camblong will move to Executive Chairman to focus on technical innovation [1] Innovation and Technology - The company leveraged a diverse data stream from 75 countries to launch 'Digital Twins' for lung cancer, enabling AI-driven virtual simulations for therapy selection [1]

Core Insights - Pacific Biosciences of California, Inc. (PACB) has partnered with DNAstack to create the first global federated dataset of HiFi whole genome sequencing data, aimed at enhancing rare disease research while ensuring data privacy compliance [1][2][4] Collaboration Details - The collaboration will utilize DNAstack's secure, cloud-enabled infrastructure, allowing institutions to connect their PacBio HiFi whole genome sequencing data without transferring sensitive datasets, thus enabling cross-border analysis while adhering to privacy regulations [3] - The HiFi Solves Global Consortium has expanded to nearly 30 institutions across 15 countries, linking over 10,000 HiFi whole genome sequences, which enhances statistical power for rare disease studies and streamlines workflows [4] Industry Prospects - The global long-read sequencing market is projected to grow from $538.9 million in 2024 to $1.53 billion by 2030, with a compound annual growth rate (CAGR) of 20.12% from 2025 to 2030, driven by the rising prevalence of genetic diseases [5] Other Developments - In January, PACB's HiFi whole-genome sequencing technology was adopted for a major research initiative on Sudden Unexplained Death in Childhood, and a new method called CiFi was introduced for chromosome-scale genome assemblies [6] Peer Updates - Illumina, Inc. has acquired SomaLogic for $350 million to enhance its multiomics ecosystem, while also launching TruPath Genome to improve genetic disease research capabilities [7][9]